Table 5 Geometric mean pharmacokinetic parameters of paclitaxel on day 1 and day 15a

From: Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies

  n Day 1 n Day 15
50 mg m −2 paclitaxel+ 400 mg pazopanib+ 1000 mg lapatinib
AUC(0–), μg*h ml−1 6 2.15 (1.82, 2.54) 4 3.07 (2.80, 3.37)
CL, l h−1 m−2 6 23.2 (19.7, 27.4) 4 16.3 (14.8, 17.9)
Cmax, μg ml−1 7 1.44 (1.16, 1.80) 5 2.33 (1.55, 3.48)
t1/2, h 6 11.7 (9.3, 14.8) 4 12.6 (9.5, 16.6)
50 mg m −2 paclitaxel+ 800 mg pazopanib+ 1000 mg lapatinib
AUC(0-), μg*h ml−1 2 1.66, 2.69 3 3.06 (2.46, 3.36)
CL, l h−1 m−2 2 18.6, 30.1 3 16.3 (14.9, 20.3)
Cmax, μg ml−1 3 1.27 (1.13, 1.36) 3 1.72 (1.46, 2.27)
t1/2, h 2 10.9, 11.0 3 14.8 (10.0, 15.8)
80 mg m −2 paclitaxel+ 800 mg pazopanib+ 1000 mg lapatinib
AUC(0–), μg*h ml−1 2 5.06, 5.58 1 4.37
CL, l h−1 m−2 2 14.3, 15.8 1 18.3
Cmax, μg ml−1 3 3.32 (1.63, 4.09) 1 2.71
t1/2, h 2 10.4, 11.2 1 11.6
80 mg m −2 paclitaxel+ 400 mg pazopanib+ 1000 mg lapatinib
AUC(0-), μg*h ml−1 11 3.82 (3.38, 4.31) 9 5.23 (4.50, 6.08)
CL, l h−1 m−2 11 21.0 (18.6, 23.7) 9 15.3 (13.2, 17.8)
Cmax, μg ml−1 13 2.29 (2.06, 2.55) 9 3.00 (2.48, 3.64)
t1/2, h 11 10.8 (9.7, 12.0) 9 11.1 (9.7, 12.7)
  1. Abbreviations: AUC(0–)=area under the concentration–time curve extrapolated to infinity; CL=systemic clearance; Cmax=maximum observed concentration; t1/2=terminal half-life.
  2. aFor n=1 or 2, individual data values are listed; for n=3, data are reported as median (range); for n 4, data are reported as geometric mean (95% confidence interval).